We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunolo... Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases with a particular interest in the field of immunology. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Show more
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc. PR Newswire LONDON...
Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference PR Newswire LONDON, Sept. 9, 2024 LONDON, Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the...
Virax Biolabs to Participate at 7th European Congress of Immunology PR Newswire LONDON, Aug. 29, 2024 LONDON, Aug. 29, 2024 /PRNewswire/ --Β Virax Biolabs Group Limited ("Virax" or the "Company...
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East PR Newswire LONDON, Aug. 28, 2024 LONDON, Aug...
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares PR Newswire LONDON, Aug. 23, 2024 LONDON, Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs...
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares PR Newswire LONDON, Aug. 21, 2024 LONDON, Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1098 | -6.27428571429 | 1.75 | 1.93 | 1.62 | 188271 | 1.76815173 | CS |
4 | -1.0798 | -39.6985294118 | 2.72 | 3.02 | 1.5304 | 474412 | 2.13400517 | CS |
12 | 0.5202 | 46.4464285714 | 1.12 | 8.9999 | 0.9541 | 4995937 | 4.80303103 | CS |
26 | 0.9192 | 127.489597781 | 0.721 | 8.9999 | 0.6 | 3061621 | 4.12022479 | CS |
52 | -1.3908 | -45.8858462554 | 3.031 | 8.9999 | 0.6 | 1602449 | 4.02389894 | CS |
156 | -198.3598 | -99.1799 | 200 | 290 | 0.6 | 1476363 | 24.4578255 | CS |
260 | -198.3598 | -99.1799 | 200 | 290 | 0.6 | 1476363 | 24.4578255 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions